Skip to main navigation
Aligos Therapeutics Logo

    Investor Relations

  • Overview
  • Stock
    Stock Quote & Chart Analyst Coverage
  • News & Events
    News Releases Investor Calendar Presentations
  • Financials
    SEC Filings Quarterly Results
  • Governance
    Governance Highlights Committee Composition
  • Resources
    Investor FAQs Email Alerts Contact IR

News Releases

Apr 14, 2021
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to
Mar 23, 2021
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initial Public
Mar 10, 2021
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
The first drug candidate in Aligos’s chronic hepatitis B portfolio to be administered to CHB patients SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to
Mar 08, 2021
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a
Feb 03, 2021
Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will deliver four
Jan 07, 2021
Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D.,

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © Aligos Therapeutics 2021